Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Hormone-refractory Prostate Cancer
NCT00570700Phase 2Completed
- Sponsor
- University of California, Irvine
- Start
- Jul 2007
- Primary completion
- Feb 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in prostate cancer (PCa), sponsored by University of California, Irvine. Started Jul 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00570700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570700.